U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07799129) titled 'Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia' on Aug. 27.
Brief Summary: EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This Phase 2 clinical study comprises two phases: a randomized, double-blind, placebo parallel-controlled core study and an open-label extension study.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Mixed Dyslipidemia
Intervention:
DRUG: EDP167 100mg
EDP167 100 mg or volume-matched placebo sc once ...